MedTrace Logo

Genomics and COVID-19 Vaccine Adverse Events

NCT05212792 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6325

Last updated 2026-05-01

No results posted yet for this study

Summary

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide.

Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events.

The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).

Conditions

  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

COVID-19 vaccines

Any licensing COVID-19 vaccine platform

Sponsors & Collaborators

Principal Investigators

  • Bruce Carleton, PharmD · University of British Columbia

Eligibility

Min Age
5 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-24
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212792 on ClinicalTrials.gov